On Q3 Earnings Call, Lilly Vows To Stay Its Current Course Despite Late-Stage Pipeline Setbacks
This article was originally published in The Pink Sheet Daily
Executive Summary
As analysts call for transformative M&A, executives talked up Lilly's modest diversification efforts, including its animal health business, Elanco, and strong Japanese sales.
You may also be interested in...
Alcresta Investment Reflects Omega Market Growth
Alcresta is developing omega-3 and -6 fatty acid supplements that are more easily digested and absorbable. Founders Alexey Margolin and Robert Gallotto look to repeat the success they had in 2010 when they sold an earlier nutritionals start-up for $180 million.
Alcresta Investment Reflects Omega Market Growth
Alcresta is developing omega-3 and -6 fatty acid supplements that are more easily digested and absorbable. Founders Alexey Margolin and Robert Gallotto look to repeat the success they had in 2010 when they sold an earlier nutritionals start-up for $180 million.
Servier, MacroGenics Forge Option Deal For Cancer Drug
The French pharma acquires the right to license the antibody MGA271, which has received strong interest since BMS’s Yervoy was approved in March.